Samuel Whiting is Chief Medical Officer of Tempest Therapeutics, Inc.. Currently has a direct ownership of 9,573 shares of TPST, which is worth approximately $8,041. The most recent transaction as insider was on Jul 02, 2024, when has been sold 4,672 shares (Common Stock) at a price of $2.13 per share, resulting in proceeds of $9,951. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 9.57K
0% 3M change
403.58% 12M change
Total Value Held $8,041

Samuel Whiting Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jul 02 2024
BUY
Open market or private purchase
$9,951 $2.13 p/Share
4,672 Added 32.8%
9,573 Common Stock
Jan 06 2022
BUY
Open market or private purchase
$8,160 $4.8 p/Share
1,700 Added 47.21%
1,901 Common Stock
Jun 25 2021
BUY
Grant, award, or other acquisition
-
201 Added 50.0%
201 Common Stock
SW

Samuel Whiting

Chief Medical Officer
South San Francisco, CA

Track Institutional and Insider Activities on TPST

Follow Tempest Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TPST shares.

Notify only if

Insider Trading

Get notified when an Tempest Therapeutics, Inc. insider buys or sells TPST shares.

Notify only if

News

Receive news related to Tempest Therapeutics, Inc.

Track Activities on TPST